Skip to content

A retrospective study comparing the safety and effectiveness of transcatheter repair versus surgical repair for mitral valve regurgitation at the junction area

A Retrospective, Multicenter Observational Study Comparing the Safety and Effectiveness of Transcatheter Edge-to-Edge Repair and Surgical Repair for Commissural Mitral Regurgitation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128028
Enrollment
Unknown
Registered
2026-07-13
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate-to-severe or severe commissural mitral regurgitation or mitral regurgitation involving commissural-adjacent regions, mainly involving the anterolateral or posteromedial commissure and adjacent A1/P1 or A3/P3 segments, primarily related to degenerative or commissural mitral valve disease

Interventions

Surgical repair group:None
Transcatheter edge-to-edge repair (TEER):None

Sponsors

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age =18 years; 2.Diagnosis of moderate-to-severe or more severe commissural mitral regurgitation or mitral regurgitation involving commissural-adjacent regions, mainly involving the anterolateral or posteromedial commissure and adjacent A1/P1 or A3/P3 segments; 3.revious treatment with TEER or surgical mitral valve repair centered on the Magic Stitch technique; 4.Available baseline data, treatment records, and at least one postoperative follow-up outcome;

Exclusion criteria

Exclusion criteria: 1.The primary etiology is not degenerative or commissural-related mitral valve disease and is unsuitable for inclusion in the comparison; 2.Previous treatment with other transcatheter mitral valve therapies or prior mitral valve surgery that makes it impossible to evaluate the effect of the index treatment; 3.Severe missing key baseline or treatment data, making it impossible to determine whether the patient meets the study population definition; 4.Patients known to have previously explicitly refused the use of their clinical data for research; 5.The investigator judges that the authenticity or completeness of the data is insufficient for inclusion in the analysis;

Design outcomes

Primary

MeasureTime frame
Proportion of patients free from treatment failure at 12 months after treatment;

Secondary

MeasureTime frame
Main side effects;repeat surgery/reintervention;

Countries

China

Contacts

Public ContactXiaofeng Ye

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Xiaofengye@hotmail.com+86 21 6437 0045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026